NeoGenomics (NEO) Tops Q2 EPS by 1c

Go back to NeoGenomics (NEO) Tops Q2 EPS by 1c

BTIG Downgrades Neogenomics (NEO) to Neutral

July 27, 2016 7:34 AM EDT

BTIG downgraded Neogenomics (NASDAQ: NEO) from Buy to Neutral and removed its price target. Analyst Sean Lavin sees less compelling risk reward.

"Shares have risen 70% in less than a year. Our Buy thesis had been predicated on continued share gains, stable reimbursement, and... More